Predicting survival in early hepatocellular carcinoma

Ryder, S.
March 2005
Gut;Mar2005, Vol. 54 Issue 3, p328
Academic Journal
The article presents information related to predicting survival in early hepatocellular carcinoma. Over the past decade, non-surgical therapies for hepatocellular carcinoma (HCC) occurring on a background of cirrhosis have been established as effective. Hepatic arterial chemoembolisation has a proven survival advantage in selected patient groups, and there is now strong evidence that ablative therapies, both percutaneous alcohol injection and radiofrequency ablation, have survival benefit. In addition, HCC incidence is increasing in the Western world, mainly due to the hepatitis C epidemic and this cancer now has an increasing impact on health services.


Related Articles

  • Immunohistochemical Detection of HCV in Cirrhosis, Dysplastic Nodules, and Hepatocellular Carcinomas with Parallel-Tissue Quantitative RT-PCR. Rullier, Anne; Trimoulet, Pascale; Urbaniak, Rosa; Winnock, Maria; Zauli, Daniela; Ballardini, Giorgio; Rosenbaum, Jean; Balabaud, Charles; Bioulac-Sage, Paulette; Bail, Brigitte Le // Modern Pathology;May2001, Vol. 14 Issue 5, p496 

    Hepatitis C virus is a major risk factor for hepatocarcinogenesis in humans. In situ detection of the virus in early sequential lesions of hepatocarcinogenesis could provide information about the role of the virus in the transformation and promotion process. Parallel in situ detection of HCV...

  • High α-Fetoprotein Level in HCV- Related Nodular Liver Cell Dysplasia. Ng Fook-Hong; Chow Kai-Chiu; Cheng Chi-Sing; Kng Carolyn; Ng Wing-Fung; Wong Benjamin Chun-Yu // American Journal of Gastroenterology;Aug1999, Vol. 94 Issue 8, p2296 

    The diagnosis of hepatocellular carcinoma is generally made in patients with a mass lesion in the cirrhotic liver if the α-fetoprotein level is >1,000 ng/L. Other causes of elevation of α-fetoprotein to this extreme degree include nonseminomatous germ cell tumor and hepatic metastasis....

  • Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. Averhoff, Francisco M.; Glass, Nancy; Holtzman, Deborah // Clinical Infectious Diseases;Jul2012 Supplement 1, Vol. 55 Issue suppl_1, pS10 

    An estimated 2%–3% of the world's population is living with hepatitis C virus (HCV) infection, and each year, >350 000 die of HCV-related conditions, including cirrhosis and liver cancer. The epidemiology and burden of HCV infection varies throughout the world, with country-specific...

  • HCC risk persists 8 years after HCV eradication.  // Infectious Disease News;Jun2013, Vol. 26 Issue 6, p36 

    The article discusses the results of a study which concluded that patients with hepatitis C-induced liver cirrhosis have a long-term risk for hepatocellular carcinoma of up to 8 years after sustained virological response to antiviral therapy.

  • Hepatitis C: Symptoms.  // Hepatitis C (National Institute of Allergy/Infectious Disease);2009, p5 

    The article offers information on the symptoms of hepatitis C. It mentions that the patients suffering from hepatitis C have abdominal pain, loss of appetite and nausea or vomiting and symptoms of acute hepatitis C appear 6 to 12 weeks after exposure to the virus. It further mentions that in...

  • Eradication of Hepatitis C Virus Reduces the Risk of Hepatocellular Carcinoma in Patients with Compensated Cirrhosis. Velosa, José; Serejo, Fátima; Marinho, Rui; Nunes, Joana; Glória, Helena // Digestive Diseases & Sciences;Jun2011, Vol. 56 Issue 6, p1853 

    Background: The effect of a sustained virological response (SVR) to interferon (IFN) on clinical outcomes of hepatitis C virus (HCV)-related cirrhosis is controversial. Aims: Evaluate the effect of SVR to IFN on the incidence of hepatocellular carcinoma (HCC) and mortality in patients with...

  • A patient with hepatitis C-related liver cirrhosis and hepatocellular carcinoma who was cured with an orthotopic liver transplantation and interferon therapy. Shibata, Minoru; Yanaga, Katsuhiko; Morizane, Toshio; Yanagawa, Tatsuro; Hirakawa, Masami; Ueno, Yukihisa; Esquivel, Carlos O.; Mitamura, Keiji // Journal of Gastroenterology;2003, Vol. 38 Issue 6, p598 

    A patient with hepatitis C virus (HCV)-related liver cirrhosis and hepatocellular carcinoma (HCC) was treated successfully with an orthotopic liver transplantation (OLT) followed by interferon therapy. The 36-year-old Japanese man was diagnosed as having liver cirrhosis in 1983. HCC was detected...

  • Prevalence of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis and Prior Exposure to Hepatitis C. Vamauchi, Masayoshi; Nakahara, Masao; Maezawa, Yoshihiko; Satoh, Shyunnya; Nishikawa, Fuminori; Ohata, Mituru; Mizuhara, Yuji; Hirakawa, Junnichi; Nakajima, Hisato; Fujisawa, Kiyoshi; Toda, Gotaro // American Journal of Gastroenterology;Jan1993, Vol. 88 Issue 1, p39 

    Sixty-three patients with alcoholic cirrhosis were retrospectively studied for the prevalence of antibodies to core (P22) and nonstructural (C100) region of hepatitis C virus (HCV). The prevalence rate of anti-F22 anti-bodies in patients with alcoholic cirrhosis was higher than that of anti-C100...

  • Global control of hepatitis C: where challenge meets opportunity. Thomas, David L // Nature Medicine;Jul2013, Vol. 19 Issue 7, p850 

    We are entering an important new chapter in the story of hepatitis C virus (HCV) infection. There are clear challenges and opportunities. On the one hand, new HCV infections are still occurring, and an estimated 185 million people are or have previously been infected worldwide. Most HCV-infected...


Read the Article


Sign out of this library

Other Topics